Stryker reported its operating results for the first quarter of 2025 on May 1, 2025, demonstrating continued momentum with consolidated net sales increasing 11.9% to $5.9 billion. Organic net sales grew by a robust 10.1%, driven by a 9.4% increase in unit volume and a 0.7% contribution from higher prices. The MedSurg and Neurotechnology segment saw organic growth of 10.7%, while Orthopaedics grew 9.3% organically.
Adjusted net earnings per diluted share increased 13.6% to $2.84, surpassing analyst estimates. However, reported net earnings decreased 17.0% to $654 million, and reported diluted EPS fell 17.6% to $1.69, primarily due to higher acquisition and integration-related costs. The adjusted operating income margin expanded to 22.9%, reflecting underlying business leverage.
Based on these results and strong demand, Stryker raised its full-year 2025 organic net sales growth guidance to a range of 8.5% to 9.5%. The company reiterated its adjusted net earnings per diluted share guidance of $13.20 to $13.45, which now includes the dilutive impact from the Inari acquisition and offsets an estimated $200 million tariff impact. CEO Kevin Lobo noted that without the tariffs, the company would have raised its earnings guidance without question.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.